A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

Completed · Phase 3 · Has a placebo group

Conditions studied: Tuberous Sclerosis Complex, Seizures

In brief

This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The blinded phase only will be described in this record. Participants will receive 1 of 2 doses of GWP42003-P or matching placebo. The primary clinical hypothesis is that there will be a difference between GWP42003-P and placebo in their effect on seizure frequency.

Key facts

Study ID
NCT02544763
Run by
Jazz Pharmaceuticals
People needed
224
Starts
2016-04-06
Expected to finish
2019-02-26
Last updated by the study team
2022-09-28

Who can join

Age: 1 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.